News | Coronavirus (COVID-19) | June 30, 2020

COVID-19: Study Shows Virus Can Infect Heart Cells in Lab Dish

Research, led by Cedars-Sinai, uses stem cell technology to learn how coronavirus may directly attack heart muscle

Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

June 30, 2020 — A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus. The discovery, published today in the journal Cell Reports Medicine, was made using heart muscle cells that were produced by stem cell technology.

Although many COVID-19 patients experience heart problems, the reasons are not entirely clear. Pre-existing cardiac conditions or inflammation and oxygen deprivation that result from the infection have all been implicated. But until now, there has been only limited evidence that the SARS-CoV-2 virus directly infects the individual muscle cells of the heart.

“We not only uncovered that these stem cell-derived heart cells are susceptible to infection by novel coronavirus, but that the virus can also quickly divide within the heart muscle cells,” said Arun Sharma, Ph.D., a research fellow at the Cedars-Sinai Board of Governors Regenerative Medicine Institute and first and co-corresponding author of the study. “Even more significant, the infected heart cells showed changes in their ability to beat after 72 hours of infection.”

The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular "defense mechanisms" in an effort to help clear out the virus.

While these findings are not a perfect replicate of what is happening in the human body, this knowledge may help investigators use stem cell-derived heart cells as a screening platform to identify new antiviral compounds that could alleviate viral infection of the heart, according to senior and co-corresponding author Clive Svendsen, Ph.D.

“This viral pandemic is predominately defined by respiratory symptoms, but there are also cardiac complications, including arrhythmias, heart failure and viral myocarditis,” said Svendsen, director of the Regenerative Medicine Institute and professor of Biomedical Sciences and Medicine. “While this could be the result of massive inflammation in response to the virus, our data suggest that the heart could also be directly affected by the virus in COVID-19.”

Researchers also found that treatment with an ACE2 antibody was able to blunt viral replication on stem cell-derived heart cells, suggesting that the ACE2 receptor could be used by SARS-CoV-2 to enter human heart muscle cells.

“By blocking the ACE2 protein with an antibody, the virus is not as easily able to bind to the ACE2 protein, and thus cannot easily enter the cell,” said Sharma. “This not only helps us understand the mechanisms of how this virus functions, but also suggests therapeutic approaches that could be used as a potential treatment for SARS-CoV-2 infection.”

The study used human induced pluripotent stem cells (iPSCs), a type of stem cell that is created in the lab from a person's blood or skin cells. IPSCs can make any cell type found in the body, each one carrying the DNA of the individual. Tissue-specific cells created in this way are used for research and for creating and testing potential disease treatments.

“This work illustrates the power of being able to study human tissue in a dish,” said Eduardo Marbán, MD, Ph.D., executive director of the Smidt Heart Institute, who collaborated with Sharma and Svendsen on the study. “It is plausible that direct infection of cardiac muscle cells may contribute to COVID-related heart disease.”

The investigators also collaborated with co-corresponding author Vaithilingaraja Arumugaswami, DVM, Ph.D., an associate professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Arumugaswami provided the novel coronavirus that was added to the heart cells, and UCLA researcher Gustavo Garcia Jr. contributed essential heart cell infection experiments.

“This key experimental system could be useful to understand the differences in disease processes of related coronaviral pathogens, SARS and MERS,” Arumugaswami said.

These studies were performed under the following approvals: UCLA provided The Human Pluripotent Stem Cell Research Oversight (hPSCRO) #2020-004-01 for Human iPSC-derived cardiac and lung cells for disease modeling COVID-19, as well as protocol BUA-2020-015-003-A approved by the UCLA Institutional Biosafety Committee (IBC).

Funding: Research from the Svendsen laboratory has been supported by the National Institutes of Health under award number 5UG3NS105703 and the Cedars-Sinai Board of Governors Regenerative Medicine Institute. Arun Sharma is supported by an institutional training grant from the NIH under award number T32 HL116273.

For more information: www.cedars-sinai.org

 

Related Cardiology COVID-19 Content:

United We Stand Against COVID-19 was Overarching Message From ACC 2020 Virtual Meeting

The Cardiovascular Impact of COVID-19

VIDEO: 9 Cardiologists Share COVID-19 Takeaways From Across the U.S.

VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine and Azithromycin — Interview with Andrew D. Krahn, M.D.,

 

AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

VIDEO: CT and POCUS Emerge As Frontline Cardiac Imaging Modalities in COVID-19 Era — Interview with Geoffrey Rose, M.D.

FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

 

Cardiology Meetings Continue to be Cancelled or Go Virtual Due to COVID-19

How Cardiology Dealt With the COVID-19 Surge in New York City

Kawasaki-like Inflammatory Disease Affects Children With COVID-19 

New Research Highlights Blood Clot Dangers of COVID-19

 

VIDEO: Impact of COVID-19 on the Interventional Cardiology Program at Henry Ford Hospital — Interview with William O'Neill, M.D.

ACC COVID-19 Clinical Guidance For the Cardiovascular Care Team

The Cardiac Implications of Novel Coronavirus

More COVID-19 News Related to Cardiology

Related Content

#breakingnews The U.S. Food and Drug Administration (FDA) just granted full approval to the Pfizer/BioNTech Covid-19 vaccine for people age 16 and older. It is the first vaccine to be fully approved by the FDA, and experts say it is expected to open the door for further vaccine mandates.

Getty Images

News | Coronavirus (COVID-19) | August 23, 2021
August 23, 2021 — The U.S.
The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compromised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images #AHA #coronavirus #COVID19

The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compormised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images

News | Coronavirus (COVID-19) | August 18, 2021 | By Dave Fornell, Editor
August 18, 2021 — The U.S.
In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. ACC, HRS, ASNC, SCMR, SCCT, ASE, HFSA, STS, SCAI.

In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. 

Feature | Coronavirus (COVID-19) | July 30, 2021 | By Dave Fornell, Editor
July 30, 2021 — A coalition of 10 U.S.-based cardiovascular societies have issued a statement today in support of all
AHA president says COVID has a direct impact on the heart and preventive measures for heart disease largely went out the window during the pandemic

Getty Images

News | Coronavirus (COVID-19) | July 26, 2021
July 26, 2021 — Heart disease and stroke continue to kill more people in the U.S.
A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19.

A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19. Researchers believe statins, which attach to the ACE2 receptors, may block the virus from attaching to these same receptors. 

News | Coronavirus (COVID-19) | July 21, 2021
July 21, 2021 — In a new study from University of California San Diego School of Medicine, researchers have confirmed
New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. Getty Images
 

Feature | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — COVID-19 is m
Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months. From the study How a COVID-19 Infection Changes Blood Cells in the Long Run. Reasons for long COVID.

Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months.

News | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — Using real-time deformability cytometry, researchers at the...
Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

News | Coronavirus (COVID-19) | June 28, 2021
June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in child
The U.S. Food and Drug Administration (FDA) announced June 25 it has added a warning on the Moderna and Pfizer COVID-19 messenger RNA (mRNA) vaccine fact sheets to explain they may cause myocarditis in rare cases as a side effect. The agency said the side effect is very rare and patients generally recover quickly, but it can disportionally affect younger patients in their teens and early 20s. Getty Images

Getty Images

News | Coronavirus (COVID-19) | June 28, 2021 | Dave Fornell, Editor
June 28, 2021 — The U.S.
A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).

A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP). Getty Images

Feature | Coronavirus (COVID-19) | June 24, 2021 | By Dave Fornell, Editor
A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA)...